Price to Book Value Chart

Historical Price to Book Value Data

View and export this data back to 2000. Start Trial.
Date Value
November 13, 2026 1.490
November 12, 2026 1.508
November 11, 2026 1.706
November 10, 2026 1.824
November 09, 2026 2.091
November 06, 2026 2.001
November 05, 2026 2.132
November 04, 2026 2.148
November 03, 2026 2.132
November 02, 2026 2.061
October 30, 2026 2.155
October 29, 2026 1.973
October 28, 2026 1.966
October 27, 2026 2.075
October 26, 2026 2.913
October 23, 2026 2.925
October 22, 2026 2.961
October 21, 2026 2.819
October 20, 2026 2.380
October 19, 2026 2.333
October 16, 2026 2.416
October 15, 2026 2.511
October 14, 2026 2.463
October 13, 2026 2.534
October 12, 2026 2.534
Date Value
October 09, 2026 2.558
October 08, 2026 2.534
October 07, 2026 2.700
October 06, 2026 2.653
October 05, 2026 2.937
October 02, 2026 3.032
October 01, 2026 3.126
September 30, 2026 3.055
September 29, 2026 1.487
September 28, 2026 1.537
September 25, 2026 1.570
September 24, 2026 1.504
September 23, 2026 1.637
September 22, 2026 1.682
September 21, 2026 1.593
September 18, 2026 1.515
September 17, 2026 1.537
September 16, 2026 1.570
September 15, 2026 1.559
September 14, 2026 1.632
September 11, 2026 1.637
September 10, 2026 1.615
September 09, 2026 1.682
September 08, 2026 1.715
September 04, 2026 1.760

Price to Book Ratio Definition

Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.

Read full definition.

Price to Book Value Range, Past 5 Years

View Price to Book Value Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Price to Book Value Benchmarks

View Price to Book Value Benchmarks
Start Trial
Altimmune, Inc. 0.6996
Taysha Gene Therapies, Inc. 3.766
Agenus, Inc. --
Amgen, Inc. 17.65
Anika Therapeutics, Inc. 1.280

Price to Book Value Related Metrics

Price 0.6399
Earnings Yield -518.7%
Market Cap 2.986M